- Target disease: Leishmaniasis
- Main partners (since project start): Daiichi Sankyo, Japan
- Project start: 2017
- Funding (since project start): Department for International Development (DFID), UK; Médecins Sans Frontières/Doctors without Borders; Dutch Ministry of Foreign Affairs (DGIS), The Netherlands; Federal Ministry of Education and Research (BMBF through KfW), Germany; Global Health Innovative Technology (GHIT) Fund, Japan; Swiss Agency for Development and Cooperation (SDC), Switzerland.
In February 2016, Daiichi Sankyo and DNDi launched a High-Throughput Screening project of 40,000 compounds from Daiichi Sankyo with the goal of discovering anti-leishmaniasis and anti-Chagas disease compounds, identifying three compound series.
This project, which ended in September 2018, aimed to identify at least one progressable lead series meeting DNDi lead-stage criteria for visceral leishmaniasis and/or Chagas disease. The project milestone was reached with the identification of a progressable Chagas lead series with proven in vivo.
Current hit-to-lead efforts of the series identified from the Daiichi Sankyo Pharma Space Library focus on Chagas disease, but the project team submits any newly synthesized molecules to a Leishmania cross screen to assess potential.
Last update: February 2019